Metabolic management of brain cancer.
Malignant brain tumors are a significant health problem in children and adults. Conventional therapeutic approaches have been largely unsuccessful in providing long-term management. As primarily a metabolic disease, malignant brain cancer can be managed through changes in metabolic environment. In contrast to normal neurons and glia, which readily transition to ketone bodies (β-hydroxybutyrate) for energy under reduced glucose, malignant brain tumors are strongly dependent on glycolysis for energy. The transition from glucose to ketone bodies as a major energy source is an evolutionary conserved adaptation to food deprivation that permits the survival of normal cells during extreme shifts in nutritional environment. Only those cells with a flexible genome and normal mitochondria can effectively transition from one energy state to another. Mutations restrict genomic and metabolic flexibility thus making tumor cells more vulnerable to energy stress than normal cells. We propose an alternative approach to brain cancer management that exploits the metabolic flexibility of normal cells at the expense of the genetically defective and metabolically challenged tumor cells. This approach to brain cancer management is supported from recent studies in mice and humans treated with calorie restriction and the ketogenic diet. Issues of implementation and use protocols are presented for the metabolic management of brain cancer.
Seyfried
Thomas N
TN
Biology Department, Boston College, Chestnut Hill, MA 02467, USA. thomas.seyfried@bc.edu
Kiebish
Michael A
MA
Marsh
Jeremy
J
Shelton
Laura M
LM
Huysentruyt
Leanne C
LC
Mukherjee
Purna
P
D000328:Adult; D000818:Animals; D001932:Brain Neoplasms / Q000150:complications / Q000178:diet therapy / Q000378:metabolism / Q000628:therapy*; D031204:Caloric Restriction; D002648:Child; D055423:Diet, Ketogenic; D004195:Disease Models, Animal; D004734:Energy Metabolism / Q000502:physiology*; D005909:Glioblastoma / Q000150:complications / Q000178:diet therapy / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D051379:Mice; D028361:Mitochondrial Diseases / Q000150:complications / Q000378:metabolism / Q000628:therapy; D008954:Models, Biological